Abstract:Background: Dry powder (DP) synthetic lung surfactant may be an effective means of noninvasive delivery of surfactant therapy to premature infants supported with nasal continuous positive airway pressure (nCPAP) in low-resource settings. Methods: Four experimental DP surfactant formulations consisting of 70% of phospholipids (DPPC:POPG 7:3), 3% Super Mini-B (SMB) or its sulfur-free derivate B-YL as SP-B peptide mimic, 25% of lactose or trehalose as excipient, and 2% of NaCl were formulated using spray drying. In vitro surface activity was confirmed with captive bubble surfactometry. Surfactant particle size was determined with a cascade impactor and inhaled dose was quantified using a spontaneously breathing premature lamb lung model supported with CPAP. In vivo surfactant efficacy was demonstrated in three studies. First, oxygenation and lung compliance were monitored after intratracheal instillation of resuspended DP surfactant in intubated, ventilated, lavaged, surfactant-deficient juvenile rabbits. In dose-response studies, ventilated, lavaged, surfactant-deficient rabbits received 30, 60, 120 or 240 mg/kg of DP B-YL:Lactose or B-YL:Trehalose surfactant by aerosol delivery with a low flow aerosol chamber via their endotracheal tube. Noninvasive aerosolization of DP B-YL:Trehalose surfactant via nasal prongs was tested in spontaneous breathing premature lambs supported with nCPAP. Intratracheal administration of 200 mg/kg of Curosurf®, a liquid porcine surfactant, was used as a positive control. Results: Mass median aerosol diameter was 3.6 μm with a geometric standard deviation of 1.8. All four experimental surfactants demonstrated high surface efficacy of intratracheal instillation of a bolus of ~ 100 mg/kg of surfactant with improvement of oxygenation and lung compliance. In the dose-response studies, rabbits received incremental doses of DP B-YL:Lactose or B-YL:Trehalose surfactant intratracheally and showed an optimal response in oxygenation and lung function at a dose of 120-240 mg/kg. Aerosol delivery via nasal prongs of 1 or 2 doses of ~ 100 mg/kg of B-YL:Trehalose surfactant to premature lambs supported with nCPAP resulted in stabilization of spontaneous breathing and oxygenation and lung volumes comparable to the positive control. Conclusion: These studies confirm the clinical potential of DP synthetic lung surfactant with B-YL peptide as a SP-B mimic to alleviate surfactant deficiency when delivered as a liquid bolus or as an aerosol.

Cell-specific modulation of surfactant proteins by ambroxol treatment

Clinical effect of large dose of ambroxol in treatment of acute episode of chronic bronchitis (AECB)

Ambroxol inhalation ameliorates LPS-induced airway inflammation and mucus secretion through the extracellular signal-regulated kinase 1/2 signaling pathway.

Inhibition of Inflammatory Responses by Ambroxol, a Mucolytic Agent, in a Murine Model of Acute Lung Injury Induced by Lipopolysaccharide

[Ambroxol and protective reflexes of the respiratory tract]

The protective effects of Ambroxol in Pseudomonas aeruginosa-induced pneumonia in rats

Suppressive effects of the expectorant drug ambroxol hydrochloride on quartz-induced lung inflammation in F344 rats

Inhalation of ambroxol inhibits cigarette smoke-induced acute lung injury in a mouse model by inhibiting the Erk pathway

[Clinical results in the treatment of chronic obstructive bronchitis with ambroxol in comparison with bromhexine (author's transl)]

Effects of ambroxol on nuclear factor-kappa B signaling transduction in lipopolysaccaride-induced acute lung injury in rats

Experimentmental Study on Inhibition of Ambroxol in Airway Remodeling of Chronic Obstructive Pulmonary Disease Rat Models

Biofilm-dependent airway infections: A role for ambroxol?

Clinical Study of Inhaled Ambroxol in the Adjunctive Treatment of Lower Respiratory Tract Infection Induced by Pseudomonas Aeruginosa

Efficacy, dose-response, and aerosol delivery of dry powder synthetic lung surfactant treatment in surfactant-deficient rabbits and premature lambs

Effect of budesonide and salbutamol on surfactant properties

Clinical research on ambroxol and salbutamol inhalation in the treatment of COPD patients

Adsorption of surfactant to bronchial epithelium: possible role of receptor 'unmasking' in asthma.

Pulmonary surfactant-associated protein A enhances the surface activity of lipid extract surfactant and reverses inhibition by blood proteins in vitro

Alteration of Surfactant Proteins A and D in Bronchoalveolar Lavage Fluid of Pneumocystis Carinii Pneumonia

Evaluation of safety and efficacy of inhaled ambroxol in hospitalized adult patients with mucopurulent sputum and expectoration difficulty

Ambroxol inhibits platelet-derived growth factor production in human monocytic cells